Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
Deciphera Pharmaceuticals, Inc. (DCPH)
Today's Latest Price: $54.57 USD
0.72 (1.34%)
Updated Feb 26 1:28pm
Add DCPH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
DCPH Stock Summary
- DCPH's price/sales ratio is 133.49; that's higher than the P/S ratio of 98.19% of US stocks.
- With a year-over-year growth in debt of -91.12%, Deciphera Pharmaceuticals Inc's debt growth rate surpasses only 2.66% of about US stocks.
- In terms of volatility of its share price, DCPH is more volatile than 93.77% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Deciphera Pharmaceuticals Inc are RETA, SYBX, RCUS, OTIC, and ORMP.
- DCPH's SEC filings can be seen here. And to visit Deciphera Pharmaceuticals Inc's official web site, go to www.deciphera.com.
DCPH Daily Price Range
DCPH 52-Week Price Range
DCPH Stock Price Chart More Charts
DCPH Price/Volume Stats
| Current price | $54.57 | 52-week high | $71.11 |
| Prev. close | $53.85 | 52-week low | $19.88 |
| Day low | $53.94 | Volume | 103,052 |
| Day high | $55.19 | Avg. volume | 540,835 |
| 50-day MA | $63.23 | Dividend yield | N/A |
| 200-day MA | $40.49 | Market Cap | 2.96B |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Top Stories View All
4 Great Dividend Stocks To Profit From the Wuhan Market Crash
Best & Worst Performing Stock Industries for February 25, 2020
Best & Worst Performing Small Cap Stocks for February 25, 2020
Best & Worst Performing Mid Cap Stocks for February 25, 2020
Best & Worst Performing Large Cap Stocks for February 25, 2020
View All Top Stories
Loading social stream, please wait...